Bursting HIV's bubble: A new workflow to study HIV-1 genome-containing capsids

Updated on: October 01,2025 0

Bursting HIV's bubble: A new workflow to study HIV-1 genome-containing capsids

Updated on:October 01,2025 0

New tool helps identify unreliable research trials

Updated on: October 01,2025 0

New tool helps identify unreliable research trials

Updated on:October 01,2025 0

3D structure of human clusterin sheds light on Alzheimer's risk factor

Updated on: October 01,2025 0

3D structure of human clusterin sheds light on Alzheimer's risk factor

Updated on:October 01,2025 0

Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer

Updated on: September 30,2025 0

Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer

Updated on:September 30,2025 0

Depression remission endures five years after psilocybin trial

Updated on: September 30,2025 0

Depression remission endures five years after psilocybin trial

Updated on:September 30,2025 0

Aumolertinib + chemotherapy improves progression-free survival in NSCLC: Clinical trial

Updated on: September 30,2025 0

Aumolertinib + chemotherapy improves progression-free survival in NSCLC: Clinical trial

Updated on:September 30,2025 0

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer

Updated on: September 30,2025 0

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer

Updated on:September 30,2025 0

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Updated on: September 30,2025 0

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

Updated on:September 30,2025 0

Study finds decline in long-term benzodiazepine use among older adults, but risks remain

Updated on: September 30,2025 0

Study finds decline in long-term benzodiazepine use among older adults, but risks remain

Updated on:September 30,2025 0

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC

Updated on: September 30,2025 0

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC

Updated on:September 30,2025 0